Medical Oncology: IROX as second-line therapy for metastatic colorectal cancer.
Haller et al. demonstrated that irinotecan plus oxaliplatin (IROX) is more efficacious than irinotecan alone after fluoropyrimidine failure in advanced colorectal cancer. IROX does not change, but enriches the treatment algorithm of advanced colorectal cancer at the second-line level.